The association of miR-126-3p, miR-126-5p and miR-664-3p expression profiles with outcomes of patients with metastatic colorectal cancer treated with bevacizumab

Fiala, Ondřej; Pitule, Pavel; Hošek, Petr; Liška, Václav; Šorejs, Ondřej; Brůha, Jan; Vyčítal, Ondřej; Büchler, Tomáš; Poprach, Alexandr; Topolčan, Ondřej; Fínek, Jindřich

doi:10.1177/1010428317709283

Cited by 25 publications

(19 citation statements)

References 43 publications

(57 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The targets of the analysis were: hsa-miR-125b-5p (assay ID 000449), hsa-miR-17-5p (assay ID 002308), hsa-let-7c-5p (assay ID 000379), hsa-miR-145-5p (assay ID 002278), hsa-miR-143-3p (assay ID 002249) and hsa-miR-99a-5p (assay ID 000435). hsa-miR-16-5p (assay ID 000391) and hsa-miR-345-5p (assay ID 002186) were chosen as reference genes based on our previous experience (12). TaqMan® MicroRNA Reverse Transcription Kit (ThermoFisher Scientific) was used for the separate reverse transcription of individual genes using target specific primers from corresponding TaqMan Assays.…”

Section: Methodsmentioning

confidence: 99%

Association of miR-125b, miR-17 and let-7c Dysregulations With Response to Anti-epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With Metastatic Colorectal Cancer

Fiala¹,

Šorejs²,

Hošek³

et al. 2020

Cancer Genomics Proteomics

Self Cite

View full text Add to dashboard Cite

Background/Aim: MicroRNAs (miRs) play an important role in the regulation of cancer-related processes and are promising candidates for cancer biomarkers. The aim of the study was to evaluate the association of response to anti-EGFR monoclonal antibodies (mAbs) with selected miR expression profiles, including miR-125b, let-7c, miR-99a, miR-17, miR-143 and miR-145 in metastatic colorectal cancer (mCRC) patients. Patients and Methods: This retrospective study included 46 patients with mCRC harbouring wild-type RAS gene treated with cetuximab or panitumumab combined with chemotherapy in first-or second-line therapy. The miR expression was assessed using qRT-PCR. Results: Down-regulation of miR-125b and let-7c and up-regulation of miR-17 were found in the tumour tissue (p=0.0226, p=0.0040, p<0.0001). Objective response rate (ORR) was associated with up-regulation of miR-125b (p=0.0005). Disease control rate (DCR) was associated with up-regulation of miR-125b and let-7c (p=0.0383 and p=0.0255) and down-regulation of miR-17 (p=0.0464). MiR-125b showed correlation with progression-free and overall survival (p=0.055 and p=0.006). Conclusion: The results show that up-regulation of miR-125b is associated with higher ORR and DCR and longer survival; let-7c up-regulation and miR-17 downregulation are associated with higher DCR in mCRC patients treated with anti-EGFR mAbs. Colorectal cancer (CRC) is one of the most common malignancies whose incidence has been increasing in developed countries (1). Clinical trials have provided evidence for the efficacy and safety of monoclonal antibodies (mAbs) targeting the epidermal growth factor receptor (EGFR) represented by cetuximab and panitumumab, in the treatment of patients with metastatic CRC (mCRC). Both agents have been widely used in mCRC patients with tumours harbouring a wild-type RAS gene. Despite the standard use of RAS gene mutations as effective biomarkers predictive of resistance to anti-EGFR mAbs, there is a large proportion of patients with tumours harbouring a wild-type RAS gene who obtain poor benefit from this systemic treatment (2-9). There is therefore an urgent need for novel complementary predictive and prognostic biomarkers. MicroRNAs (miRs) are small non-coding RNAs, consisting of approximately 18-25 nucleotides that play an important role in the regulation of target gene expression. MiRs are involved in the regulation of key cancer-related processes including proliferation, differentiation, apoptosis, cell adhesion and angiogenesis (10). The role of miRs as biomarkers useful in diagnostics or prognostic estimation in cancer patients has been extensively studied.

show abstract

Section: Methodsmentioning

confidence: 99%

Association of miR-125b, miR-17 and let-7c Dysregulations With Response to Anti-epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With Metastatic Colorectal Cancer

Fiala¹,

Šorejs²,

Hošek³

et al. 2020

Cancer Genomics Proteomics

Self Cite

View full text Add to dashboard Cite

show abstract

“…In addition, Kiss et al [ 130 ] using microarray and qRT-PCR techniques revealed that miR-92b-3p, miR-3156-5p, miR-10a-5p, miR-125a-5p may be used as predictive biomarkers of response to bevacizumab/FOLFOX therapy of CRC patients with metastasis. Similarly, Fiala et al [ 118 ] showed that miR-126-3p expression is correlated with response to bevacizumab/FOLFOX treatment of CRC patients with metastasis. On the other hand, some studies showed only altered expression of various miRNAs in CRC tissues/serum samples compared to controls [ 131 , 132 ].…”

Section: Other Mirnasmentioning

confidence: 97%

“…Many recent studies attempted to identify other miRNAs in tumor tissues or plasma/serum samples as the potential diagnostic, prognostic or predictive biomarkers of CRC, e.g., miR-17, miR-19a, miR-20a [ 108 ], miR-22 [ 109 ], miR-24-3p [ 110 ], miR-26a, miR-26b [ 111 ], miR-9 [ 112 , 113 , 114 ], miR-106a [ 115 ], miR-122, miR-200 [ 116 ], miR-125a-3p [ 117 ], miR-126-3p [ 118 ], miR-139-3p [ 119 ], miR-139-5p [ 120 ], miR-148a, miR-625-3p [ 121 ], miR-181a, miR-181b [ 122 ], miR-181c [ 123 ], miR-181d [ 124 ], miR-193a-3p [ 125 ], miR-200c [ 126 , 127 ], miR-196b-5p [ 126 ], miR-223 [ 108 , 113 ], miR-375, miR-760 [ 112 ], miR-506, miR-4316 [ 128 ], miR-1290 [ 129 ]. In addition, Kiss et al [ 130 ] using microarray and qRT-PCR techniques revealed that miR-92b-3p, miR-3156-5p, miR-10a-5p, miR-125a-5p may be used as predictive biomarkers of response to bevacizumab/FOLFOX therapy of CRC patients with metastasis.…”

Section: Other Mirnasmentioning

confidence: 99%

Relevance of MicroRNAs as Potential Diagnostic and Prognostic Markers in Colorectal Cancer

Hibner

Kimsa-Furdzik

Francuz

2018

IJMS

View full text Add to dashboard Cite

Colorectal cancer (CRC) is currently the third and the second most common cancer in men and in women, respectively. Every year, more than one million new CRC cases and more than half a million deaths are reported worldwide. The majority of new cases occur in developed countries. Current screening methods have significant limitations. Therefore, a lot of scientific effort is put into the development of new diagnostic biomarkers of CRC. Currently used prognostic markers are also limited in assessing the effectiveness of CRC therapy. MicroRNAs (miRNAs) are a promising subject of research especially since single miRNA can recognize a variety of different mRNA transcripts. MiRNAs have important roles in epigenetic regulation of basic cellular processes, such as proliferation, apoptosis, differentiation, and migration, and may serve as potential oncogenes or tumor suppressors during cancer development. Indeed, in a large variety of human tumors, including CRC, significant distortions in miRNA expression profiles have been observed. Thus, the use of miRNAs as diagnostic and prognostic biomarkers in cancer, particularly in CRC, appears to be an inevitable consequence of the advancement in oncology and gastroenterology. Here, we review the literature to discuss the potential usefulness of selected miRNAs as diagnostic and prognostic biomarkers in CRC.

show abstract

“…In addition, the significance of the genetic background for lung carcinoma has been noted, with miRNA-related molecular signals mainly involved in malignant transformation. For example, we introduced miR-126, which plays a crucial role as a cancer-suppressive miRNA in the liver, pancreas, lung, colon, and stomach [ 52 , 53 , 54 , 55 , 56 , 57 ]. In lung carcinoma cells, including cell lines, miR-126 expression is suppressed, leading to the upregulation of the target gene encoding vascular endothelial growth factor [ 58 ].…”

Section: Correlation Among Smoking Cancer and Expression Of Mirnmentioning

confidence: 99%

MicroRNAs in Smoking-Related Carcinogenesis: Biomarkers, Functions, and Therapy

Fujii

Shimada

Nakai

et al. 2018

JCM

View full text Add to dashboard Cite

Long-term heavy cigarette smoking is a well-known high-risk factor for carcinogenesis in various organs such as the head and neck, lungs, and urinary bladder. Furthermore, cigarette smoking can systemically accelerate aging, and as the result, promoting carcinogenesis via changing the host microenvironment. Various inflammatory factors, hormones, and chemical mediators induced by smoking mediate carcinoma-related molecules and induce carcinogenesis. MicroRNAs (miRNAs) are a family of short noncoding RNA molecules that bind to mRNAs and inhibit their expression. Cigarette smoke induces the expression of various miRNAs, many of which are known to function in the post-transcriptional silencing of anticancer molecules, thereby leading to smoking-induced carcinogenesis. Analysis of expression profiles of smoking-induced miRNAs can help identify biomarkers for the diagnosis and prognosis of smoking-related cancers and prediction of therapeutic responses, as well as revealing promising therapeutic targets. Here, we introduce the most recent and useful findings of miRNA analyses focused on lung cancer and urinary bladder cancer, which are strongly associated with cigarette smoking, and discuss the utility of miRNAs as clinical biomarkers.

show abstract

The association of miR-126-3p, miR-126-5p and miR-664-3p expression profiles with outcomes of patients with metastatic colorectal cancer treated with bevacizumab

Cited by 25 publications

References 43 publications

Association of miR-125b, miR-17 and let-7c Dysregulations With Response to Anti-epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With Metastatic Colorectal Cancer

Association of miR-125b, miR-17 and let-7c Dysregulations With Response to Anti-epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With Metastatic Colorectal Cancer

Relevance of MicroRNAs as Potential Diagnostic and Prognostic Markers in Colorectal Cancer

MicroRNAs in Smoking-Related Carcinogenesis: Biomarkers, Functions, and Therapy

Contact Info

Product

Resources

About